MedTrace Logo

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00078338 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 764

Last updated 2018-06-27

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Rebif®

Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).

DRUG

Copaxone®

Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).

Sponsors & Collaborators

Principal Investigators

  • Medical Responsible · Merck KGaA, Darmstadt, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-16
Primary Completion
2006-11-28
Completion
2006-11-28

Countries

  • United States
  • Argentina
  • Austria
  • Brazil
  • France
  • Germany
  • Italy
  • Netherlands
  • Russia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00078338 on ClinicalTrials.gov